The beneficial effects of glycoprotein IIb/IIIa receptor antagonists in preventing ischemic complications during percutaneous coronary intervention have been established in a series of controlled ...

Coronary heart disease (CHD) is the most common cause of death in the UK. It is a progressive disease. The first presenting symptom is often stable angina (pain in the chest on exertion), which may ...

Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI) ...

The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) ...

The low rate of intracranial hemorrhage in these trials suggests that, at least in the patient population included in clinical trials, there is no increased risk in comparison to control arms of ...

When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has acute coronary syndromes ...